Page 53 - MemoriaEHD-Eng

www.ciberehd.org

• B r, N F, L Fs, J r, a a, D M. Extracorporeal albumin
Most relevant añareseveNsarseNaLaNLBiLLosoLLiNger
dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver
scientific failure: the RELIEF trial.Hepatology. 2013 Mar;57(3):1153-62.

articles
• ripoLL C, geNesCà J, arauJo iK, graupera i, augustiN s, teJeDor M. Rebleeding prophylaxis
improves outcomes in patients with hepatocellular carcinoma. A multicenter case-

control study.Hepatology. 2013 Dec;58(6):2079-88.

• Moreau r, JaLaN r, giNes p, pavesi M, aNgeLi p, CorDoBa J. Acute-on-chronic liver failure
is a distinct syndrome that develops in patients with acute decompensation of cirr-

hosis.Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9.

• riNCóN D, Lo iaCoNo o, teJeDor M, herNaNDo a, ripoLL C, CataLiNa Mv. Prognostic value
of hepatic venous pressure gradient in patients with compensated chronic hepatitis

C-related cirrhosis.Scand J Gastroenterol. 2013 Apr;48(4):487-95.

From the perspective of research activity, we would like to highlight two important
Highlights
clinical studies that were published in 2013. The first one is the most ambitious stu-
ñ
dy in the literature regarding the treatment of patients with acute-on-chronic liver ó
disease using bio-artificial liver assist devices. This European multi-center clinical

trial was coordinated by the group and involved the participation of researchers

from several groups of the CIBER (Hepatology 2013).
The group also led an observational multicenter study involving the participation of

several groups of the CIBER that aimed to evaluate the prognosis of patients with

variceal hemorrhage and hepatocellular carcinoma (Hepatology 2013). This study
provides the rationale for optimizing the treatment of this serious complication in

clinical practice.

From the perspective of research facilities, it is important to highlight the profound

remodelling of our group’s research laboratory, which was possible due to the cola-
boration between the CIBEREHD and the Instituto de Investigación Sanitaria Gre-

gorio Maran. We hope that this improvement will generate a relevant bibliometric
impact in the short term regarding experimental studies.

Our group obtained funding as IP (Luis Menchén) for a project in the line of inflam-

matory bowel disease and intestinal epithelial permeability in the 2013 call of the

Instituto de Salud Carlos III (proyectos de investigación en salud). This circum-
stance reflects the capacity of several components of our group to obtain funding

in competitive calls.

Finally, we directed and defended two Doctoral Thesis in the Universidad Complu-

tense.

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

53